Clinical trials: HIV/AIDS
HIV (Human Immunodeficiency Virus), AIDS (Acquired Immunodeficiency Syndrome)
Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms
The purpose of this study is to use technology to improve symptom status and ultimately improve patient centered outcomes in people living with HIV/AIDS (PLWHA).
- Trial name
- VIP-HANA (NCT03182738)
- Testing
- VIP app without HIV-related symptom strategies., VIP app that delivers HIV-related symptom strategies.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Columbia University
Smoking Cessation, HIV
TMS for Smoking Cessation in PLWHA Cessation in People Living With HIV/AIDS (PLWHA)
The pilot study proposal aims to modulate craving and attentional bias towards smoking cues in 40 people living with HIV/AIDS (PLWHA) using transcranial magnetic stimulation (TMS), with functional MRI (fMRI) brain correlates.
- Conditions
- Smoking Cessation, HIV, Craving
- Trial name
- NCT04936594
- Testing
- iTBS, TMS
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Gopalkumar Rakesh
HIV, Pre-exposure Prophylaxis
The Development of a Mobile-based App to Increase Uptake of Pre-Exposure Prophylaxis (PrEP) by Men Who Have Sex With Men in China
This study aims to use a mini-application on the popular Chinese social media mobile platform, WeChat, to improve HIV pre-exposure prophylaxis (PrEP) uptake among at-risk men who have sex with men (MSM).
- Trial name
- NCT04426656
- Testing
- Phone application
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Syphilis, HIV Infections
Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting
The purpose of this study is to determine if a strategy utilizing the Chembio HIV/syphilis rapid point-of-care (POC) test for diagnosis of HIV and syphilis in pregnant women attending prenatal clinics in Guatemala will increase…
- Trial name
- NCT07498153
- Testing
- Chembio HIV/Syphilis rapid POC test
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- The University of Texas Health Science Center, Houston
Anal Cancer, High-grade Squamous Intraepithelial Lesion
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
The randomized phase of the trial compared topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL).
- Conditions
- Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
- Trial name
- ANCHOR (NCT02135419)
- Testing
- imiquimod, fluorouracil, infrared photocoagulation therapy
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 4,446 people
- Sponsor
- AIDS Malignancy Consortium
Human Immunodeficiency Virus (HIV)
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
This study is a Phase II single arm, open-label, multicenter, study of 50 human immunodeficiency virus-1 (HIV) infected adult patients, all of whom will receive etravirine (ETR) 400mg and DRV/r 800/100mg each given orally once…
- Trial name
- INROADS (NCT01199939)
- Testing
- Etravirine, Ritonavir, Darunavir
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 54 people
- Sponsor
- Tibotec, Inc
Hepatitis C Infection With HIV Co-Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with acute genotype 1 or 4 hepatitis C virus (HCV)…
- Trial name
- NCT02457611
- Testing
- LDV/SOF
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
Alcohol; Harmful Use, Binge Drinking
Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women
African American (AA) women are disproportionately affected by HIV/AIDs. The major risk factor for HIV acquisition among AA women is high-risk heterosexual sex, including unprotected vaginal and anal sex, and sex with a high-risk…
- Conditions
- Alcohol; Harmful Use, Binge Drinking, Risk Behavior, HIV Infection
- Trial name
- NCT01125371
- Testing
- Computerized brief alcohol intervention + IVR booster calls, Computerized brief alcohol intervention, Attention Control
- Where
- United States
- Volunteers
- 439 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV-1-infection
Kenya HIV Self-Testing in PrEP Delivery
In a three-arm, randomized trial, the investigators will test the use of HIV-1 self-testing to decrease the frequency and burden of clinic visits for PrEP while resulting in equivalent PrEP adherence and HIV testing.
- Trial name
- NCT03593629
- Testing
- 6-month PrEP + blood-based HIV self-test, 6-month PrEP + oral fluid HIV self-test
- Where
- Kenya
- Volunteers
- 790 people, healthy volunteers welcome
- Sponsor
- University of Washington
Hepatitis C, HIV Infections
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV…
- Trial name
- NCT00983853
- Testing
- peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 62 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
HIV Infection
Single DermaVir Immunization in HIV-1 Infected Patients on HAART
DermaVir is a plasmid DNA-containing synthetic nanomedicine. It is administered topically with DermaPrep to target Langerhans cells.
- Trial name
- GIHU004 (NCT00712530)
- Testing
- DermaVir, HAART
- Where
- Hungary
- Volunteers
- 9 people
- Sponsor
- Genetic Immunity
HIV Infections, Sexually Transmitted Infections
Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women
The purpose of this program evaluation is to determine whether the Health Love Workshop, a group-level HIV behavioral intervention, reduces HIV-related sex risk behaviors and increases HIV protective behaviors of African American…
- Trial name
- NCT00362375
- Testing
- Healthy Love Workshop, HIV/AIDS 101 Workshop
- Where
- United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Contraceptive Usage, Opioid Dependence
Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II
Nearly 9 of every 10 pregnant opioid-dependent women report that the current pregnancy was unintended and the majority of non-pregnant opioid-maintained women do not use contraception or use less effective methods like condoms.
- Trial name
- NCT02411357
- Testing
- Treatment as usual, WHO contraception protocol, Incentives
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- University of Vermont
HIV-1 Infection
Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
The objective of this study is to evaluate the safety and efficacy of a regimen containing cobicistat-boosted atazanavir (ATV+COBI) plus emtricitabine/tenofovir disoproxil fumarate (Truvada®; FTC/TDF) versus ritonavir-boosted…
- Trial name
- NCT00892437
- Testing
- COBI, RTV, ATV
- Where
- 31 sites in United States
- Volunteers
- 85 people
- Sponsor
- Gilead Sciences
Tuberculosis
Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis
Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed.
- Trial name
- NCT00082173
- Testing
- Moxifloxacin
- Where
- Brazil
- Volunteers
- 170 people
- Sponsor
- Johns Hopkins University
HIV
Eplerenone in HIV Associated Abdominal Fat Accumulation
The purpose of this study is to test the effects of a drug, eplerenone, along with lifestyle modification to affect sugar metabolism, body fat distribution, and cardiovascular health in HIV-infected individuals.
- Trial name
- NCT01405456
- Testing
- Eplerenone and lifestyle
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
HIV, Cardiovascular Diseases
Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications
People infected with HIV have a greater risk of developing cardiovascular disease than people not infected with HIV. This may be due to increased inflammation brought on by either the HIV infection itself or the use of…
- Conditions
- HIV, Cardiovascular Diseases, Atherosclerosis
- Trial name
- NCT00796822
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Indiana University
Alexithymia, HIV
Role of CBD in Improving Alexithymia
Given the treatments that are available today for HIV disease, people living with HIV (PLWH) can generally expect good medical outcomes.
- Trial name
- ACBD (NCT05832281)
- Testing
- Purysis CBD
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Diego
Infection, Human Immunodeficiency Virus
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults
The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.
- Trial name
- NCT02415595
- Testing
- BMS-955176, EFV, TDF/FTC
- Where
- 64 sites in United States, Argentina and 10 more
- Volunteers
- 210 people
- Sponsor
- ViiV Healthcare
Smallpox
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
The main purpose of this clinical trial is to generate additional safety data in a highly immunocompromised population. HIV-infected persons are considered excellent candidates to represent the highly immunocompromised population…
- Trial name
- NCT02038881
- Testing
- IMVAMUNE®
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Bavarian Nordic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.